← Back to Home

Hanmi’s AI-Designed Weight-Loss Drug Enters Valuation, but Licensing Prospects Remain Ahead of Clinical Evidence

iM Securities raised its price target for Hanmi Pharmaceutical to KRW 650,000, reflecting the value of drug candidate HM17321 and licensing income. The program, still in Phase 1 clinical trials, brings AI design into commercial development while highlighting the evidence gap between deal value and efficacy in humans.

By SURL BioNews

AI-designed weight-loss drugs are beginning to play a tangible role in pharmaceutical company valuations. On October 8, South Korea’s iM Securities raised its price target for Hanmi Pharmaceutical from KRW 600,000 to KRW 650,000, maintaining a “Buy” rating. Its reasons included the development value of drug candidate HM17321 and anticipated licensing income. However, the revision reflects a reassessment of commercial prospects; it was not accompanied by new clinical data sufficient to establish weight-loss efficacy.

The Korea Economic Daily and ChosunBiz cited analyst 鄭載元 as explaining that HM17321’s sequence was designed and its selectivity optimized using Hanmi’s proprietary HARP-PSAR platform, and that a licensing agreement totaling USD 2.3 billion was reached with Genentech in August this year. This places AI’s application in the design of a specific drug candidate; however, the total licensing deal value and the payments that may actually be received still need to be understood separately.

This R&D strategy also raises the question of where the data come from. The analyst believes that publicly available data in the peptide field are relatively limited, and that the experimental data Hanmi has accumulated over years of developing long-acting peptides could provide a competitive foundation for the platform. However, these reports did not provide the scale of the training data, independent test results, or direct comparisons with conventional design methods. They therefore do not yet allow quantification of how much AI has improved design efficiency or success rates.

Clinical evidence is also at an early stage. ChosunBiz and Financial News both reported that HM17321 is undergoing Phase 1 clinical trials; the reports did not provide complete details on participant numbers, dose groups, the extent of weight loss, or safety results. A major pharmaceutical company’s willingness to invest in development is a signal of commercial support, but whether the candidate can deliver sustained improvements in body weight, and whether its risks are acceptable, remain questions for subsequent human studies.

The valuation assumptions disclosed by ChosunBiz translate this uncertainty into numbers: using a risk-adjusted net present value method, iM valued HM17321 at approximately KRW 201.3 billion, assuming commercialization in 2033, global peak annual sales of USD 2 billion, a royalty rate of 10%, and a cumulative probability of success of 10.4%. These are all inputs to an analytical model, rather than an established launch timeline, sales commitments, or a success rate measured in trials.

The treatment of anticipated income also explains another part of the price-target increase. According to ChosunBiz, an anticipated upfront payment of approximately KRW 260 billion was excluded from the candidate’s valuation above and included instead in the value of the operating business. In other words, income that may be recognized in the near term and returns from a new drug that may materialize only years later affected the analyst’s assessment of the company separately.

Hanmi’s weight-loss portfolio is also moving toward product launch. Financial News reported that its long-acting GLP-1 drug efpeglenatide received approval from the South Korean regulatory authority on October 7, leaving the company pursuing both commercialization of an existing product and development of a next-generation candidate. The former will be tested on pricing, supply, and clinical use; the latter still needs to accumulate evidence in humans. For HM17321, the next meaningful advance will be clinical data sufficient to evaluate the results of its design.

References

  1. BigGo Finance
  2. The Korea Economic Daily
  3. ChosunBiz
  4. Financial News